Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting

Tenax Therapeutics has announced a temporary pause in enrollment for its LEVEL-2 trial of TNX-103 to amend the trial criteria. The company is also requesting a meeting with the FDA to discuss these changes. This development may impact the timeline of the trial and future regulatory approvals.